NeurologyRADiaNTNCT07014982
Remote Assessment of Digital Neurologic Testing
A study testing Guided Meditation in people with Neurology, run by Mayo Clinic at 1 site in United States.
Trial summary
The RADiaNT study investigates whether guided meditation, using the Muse™ headband and biofeedback app, can improve sleep, mood, and cognitive performance, aiming to assess its impact on mental and emotional well-being. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Neurology
- What is being tested?
- Guided Meditation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jul 2026to Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Cognition unimpaired or mild cognitive impairment
- Fluent in English
- United States resident
- Able to tolerate wearing Muse headband
- basic competence in using electronic devices (Smartphone or tablet) to engage with the Muse application and complete digital surveys and assessments
Who cannot join
- Neurological and Brain Disorders
- Not Fluent in English
- Not a US Resident
- Unable to tolerate wearing Muse Headband
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Remote Assessment of Digital Neurologic Testing (RADiaNT)
The RADiaNT study investigates whether guided meditation, using the Muse™ headband and biofeedback app, can improve sleep, mood, and cognitive performance, aiming to assess its impact on mental and emotional well-being.
- Conditions
- Neurology
- Being tested
- Guided Meditation
- Keywords
- Neurology
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Guided MeditationBehavioural
Participants who complete guided meditation will be asked to meditate for 5 minutes a day, five times a week for two 6-week periods.
| Study group | Role | What they receive |
|---|---|---|
| Guided Meditation | Experimental | This cohort will be practicing guided meditation for 5 days/week, five minutes a day for 6 weeks. Then there will be a period of testing followed by another 6 week period of practicing guided meditation. Receives: Behavioral: Guided Meditation |
| Standard of Care | No intervention | This cohort will be asked to complete neurologic testing at baseline, interim, and conclusion periods while conducting NO guided meditation throughout the duration of the study. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Duration in slow wave sleep
Total duration of sleep time spent in slow wave sleep (delta), reported in minutes
Measured: 17 weeks
Proportion in slow wave sleep
Proportion is the percentage of sleep time spent in slow wave sleep (delta)
Measured: 17 weeks
Perceived Stress Scale
Investigators will ask patients to answer the PSS questionnaire at the beginning, interim, and end of the study to see if there were any improvements in sleep quality over the intervention periods. This questionnaire is on a scale that scores 0-40, with the higher the score being a higher level of stress.
Measured: 17 weeks
Secondary outcomes (4)
Patient Health Questionnaire 9-item (PHQ-9)
The Patient Health Questionnaire 9-item (PHQ-9) scale used to assess severity of depression. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score ranges from 0 to 27 where 0 is no depression, 1-4 is minimal depression, 5-9 is mild depression, 10-14 is moderate depression, and 15-19 is moderately severe depression and 20-27 severe depression.
Measured: 17 weeks
General Anxiety Disorder 7-item (GAD-7)
The General Anxiety Disorder 7-item (GAD 7) scale to assess severity of generalized anxiety disorder. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." Total score for the seven items ranges from 0 to 21 where 0 is no anxiety, 1-4 is minimal anxiety, 5-9 is mild anxiety, 10-14 is moderate anxiety, and 15-21 is severe anxiety.
Measured: 17 weeks
Cognitive Performance
Investigators will test patients' cognitive performance at the beginning, interim, and conclusion of the study using Mayo Speech Test.
Measured: 17 weeks
Cognitive Performance
Investigators will test patients' cognitive performance at the beginning, interim, and conclusion of the study using Mayo Test Drive.
Measured: 17 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2025
- Study start1 Jul 2026 (estimated)
- Primary completionAug 2026 (estimated)
- Study completionAug 2026 (estimated)
Why it stopped: Resource reallocation
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NeurologyStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study will have two cohorts; one intervention cohort and one control cohort.
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, David T. Jones, Mayo Clinic
- Investigators
- David Jones, MD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07014982
- Sponsor's protocol ID
- 24-013687
- Acronym
- RADiaNT
- Status last verified
- Sep 2026
- First submitted
- 15 May 2025
- Last updated
- 8 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Remote Assessment of Digital Neurologic Testing (RADiaNT)
- ClinicalTrials.gov ID
- NCT07014982
- Acronym / sponsor ID
- RADiaNT / 24-013687
- Conditions
- Neurology
- Keywords
- Neurology
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Resource reallocation
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 1 Jul 2026 (estimated)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Aug 2026 (estimated)
- First posted
- 11 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The RADiaNT study investigates whether guided meditation, using the Muse™ headband and biofeedback app, can improve sleep, mood, and cognitive performance, aiming to assess its impact on mental and emotional well-being.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This study will have two cohorts; one intervention cohort and one control cohort.
| Arm | Type | Receives |
|---|---|---|
| Guided Meditation | Experimental | Behavioral: Guided MeditationThis cohort will be practicing guided meditation for 5 days/week, five minutes a day for 6 weeks. Then there will be a period of testing followed by another 6 week period of practicing guided meditation. |
| Standard of Care | No intervention | –This cohort will be asked to complete neurologic testing at baseline, interim, and conclusion periods while conducting NO guided meditation throughout the duration of the study. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Cognition unimpaired or mild cognitive impairment
- Fluent in English
- United States resident
- Able to tolerate wearing Muse headband
- basic competence in using electronic devices (Smartphone or tablet) to engage with the Muse application and complete digital surveys and assessments
Key exclusion criteria (4 listed)
- Neurological and Brain Disorders
- Not Fluent in English
- Not a US Resident
- Unable to tolerate wearing Muse Headband
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Guided MeditationParticipants who complete guided meditation will be asked to meditate for 5 minutes a day, five times a week for two 6-week periods. | Behavioural | Guided Meditation |
Primary outcome
Duration in slow wave sleep
Time frame: 17 weeks
Total duration of sleep time spent in slow wave sleep (delta), reported in minutes
Proportion in slow wave sleep
Time frame: 17 weeks
Proportion is the percentage of sleep time spent in slow wave sleep (delta)
Perceived Stress Scale
Time frame: 17 weeks
Investigators will ask patients to answer the PSS questionnaire at the beginning, interim, and end of the study to see if there were any improvements in sleep quality over the intervention periods. This questionnaire is on a scale that scores 0-40, with the higher the score being a higher level of stress.
4 secondary outcomes
Patient Health Questionnaire 9-item (PHQ-9)
Time frame: 17 weeks
General Anxiety Disorder 7-item (GAD-7)
Time frame: 17 weeks
Cognitive Performance
Time frame: 17 weeks
Cognitive Performance
Time frame: 17 weeks
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Neurology
RecruitingObservational study
Pharmacogenomics of Stimulant Treatment Response
Attention-Deficit/ Hyperactivity Disorder (ADHD)
RecruitingObservational study
Triage Survey for Neurology Research Eligibility
Alzheimer Disease
Recruiting
The Effectiveness of Conservative Treatment in Patients With Complex Regional Pain Syndrome.
CRPS (Complex Regional Pain Syndromes)
Active, not recruitingObservational study
PAMNEU - Memory in Neurology
Cognitive Impairment
Not yet recruiting
Effectiveness of an Advanced Practice Nurse-Led Health Education Program (APN-HEALTH)
Neurology
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
David Jones, MD principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Guided Meditation in people with Neurology, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 8 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Duration in slow wave sleep (time frame: 17 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Sep 2026.